Next Article in Journal
Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Tumour Entity with a Short History. A Review on Challenges in Our Microscopes, Molecular and Ultrasonographic Profile
Previous Article in Journal
An Efficient Multi-Level Convolutional Neural Network Approach for White Blood Cells Classification
 
 
Case Report
Peer-Review Record

Choroidal and Choriocapillaris Morphology in Pan-FGFR Inhibitor-Associated Retinopathy: A Case Report

Diagnostics 2022, 12(2), 249; https://doi.org/10.3390/diagnostics12020249
by Giuseppe Fasolino †, Laura Moschetta *,†, Jacques De Grève, Pieter Nelis, Pierre Lefesvre and Marcel Ten Tusscher
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Diagnostics 2022, 12(2), 249; https://doi.org/10.3390/diagnostics12020249
Submission received: 29 December 2021 / Revised: 16 January 2022 / Accepted: 18 January 2022 / Published: 20 January 2022
(This article belongs to the Section Optical Diagnostics)

Round 1

Reviewer 1 Report

This is a well-presented case report. Attached is my comment.

This is a well-presented case report that correlates the emerging anticancer pan-FGFR Inhibitor or erdafitinib with development of retinopathy and macular changes. Choroidal thickness and choriocapillaris flow void were respectively measured by macular optical coherence tomography (OCT) and angiography (OCT-A). Data were collected at baseline, at one month and at two months follow-up from start of Erdafitinib in a single case of pulmonary angiosarcoma. Choroidal and choriocapillaris morphology showed stable choroidal thickness and choriocapillaris flow void at FGFRAR onset and relapse. The study concludes that erdafitinib associated retinopathy in this patient includes a bilateral serous neuro-1retinal detachment but was not associated with significant macular alteration by OCT-A and does not seem to match pachychroid spectrum disorder definition.

This case report sets a clinical foundation for further future investigation of the underlying molecular and cellular mechanism for FGFR inhibitor-induced retinopathy.

Author Response

Dear Reviewer 1,

We want to thank you for your professional commentary and for taking the time to read and improve our work. 

In the reviewed version you can find some little adjustments of our case report.

Author Response File: Author Response.pdf

Reviewer 2 Report

Please add to the title that is only a case report

Add to the text that the patient wasn´t under any other medication (steroids)

Spaide in written in the text as Spaid

Use most common abbreviation (FA por fluorescein angiography, FAF for fundus autofluorescence)

Choroidal thickness is presented only once as an abbreviation

You cannot conclude that there are not changes in the choroid with only one case. You should point that the choroid was normal in you subject

 

Author Response

Dear reviewer 2,

Thank you for your kind reply, your time and your contribute to improve our case report. 

-Please add to the title that is only a case report

Updated as suggested: line 3

-Add to the text that the patient wasn´t under any other medication (steroids)

Updated as suggested: line 53

-Spaide in written in the text as Spaid

Updated as suggested: line 96

-Use most common abbreviation (FA por fluorescein angiography, FAF for fundus autofluorescence)

Updated as suggested: lines 73,74, 156

-Choroidal thickness is presented only once as an abbreviation

Updated as suggested: lines 18,21,109, 124, 126, 176

-You cannot conclude that there are not changes in the choroid with only one case. You should point that the choroid was normal in you subject

Updated as suggested: lines 165,173

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

Authors have changed all the suggestions

Back to TopTop